Viral vectors

Viral vector production: top 3 design considerations

Jul 20, 2020

Peter Walters is featured in Pharma Manufacturing’s Engineering Angles column, with a piece entitled “Don’t pigeonhole your viral vector production.”

If your organization is planning to create capacity for advanced therapy medicinal products (ATMP) or viral vector production, there are three key engineering considerations to take into account:

  1. Facility current good manufacturing practice (cGMP) flows
  2. Base efficiency
  3. Airflow control

These considerations are relatively easy to underestimate because in many ways the technology behind production seems similar to the production of monoclonal antibodies.

If your production requirements are higher than your available square footage, and a new build is not an option, design becomes a balancing act. You’ll need to come to grips with what you can sacrifice and still meet your original production goals, and ensure that any retrofit will not pigeonhole your facility’s future capabilities.

Read the full article here.